{"success":true,"data":{"pressRelease":{"id":"154580","rtpr_id":"nNFCbJzVY4-20260928","ticker":"HIMS","exchange":"NYSE","all_tickers":["HIMS"],"title":"Hims & Hers Health (HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS","author":"Newsfile Corp","published_at":"2026-09-28T20:25:18.436Z","article_body":"San Francisco, California--(Newsfile Corp. - September 28, 2026) - Hims & Hers\nHealth, Inc. (NYSE: HIMS) and certain company executives now face a securities\nclass action lawsuit stemming from the FTC's sweeping federal complaint\nagainst the company in which the Commission accuses Hims of serious business\nmisconduct.\n\nHagens Berman, which is actively investigating the alleged claims, encourages\nHIMS investors who suffered substantial losses to submit your losses now\n(https://api.newsfilecorp.com/redirect/Jk3XxIYqQn).\n\nClass Period: Aug. 4, 2025 – July 29, 2026\nLead Plaintiff Deadline: Nov. 2, 2026\nVisit Hims Investigation Page: www.hbsslaw.com/hims\nDirect Contact Email: HIMS@hbsslaw.com\nFirm Telephone: 844-916-0895\n\nHims & Hers Health ($HIMS) Securities Class Action\n\nThe lawsuit is focused on the propriety of Hims' repeated assurances that\n\"[w]e have developed and maintain policies and procedures with respect to\nhealth information and personal information that we use or disclose in\nconnection with our operations, including the adoption of administrative,\nphysical, and technical safeguards to protect such information.\"\n\nThe complaint alleges that Hims: (1) shared consumers' health information with\nthird-party advertising platforms; (2) charges consumers for prescriptions\nalmost immediately after they submit intake forms, despite telling them that\nthey will be able to consult with a medical provider to find a treatment that\nis \"right for them[;]\" and (3) as a result, would be subject to heightened\nregulatory scrutiny and likely to incur fees and penalties.\n\nWhat Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit\nBreakdown\n\nThe securities class action cites the July 29, 2026 federal complaint filed\nagainst Hims by the FTC—alongside co-plaintiffs the State of Utah and the\nCounty of Los Angeles (representing California).\n\nAfter an extensive investigation by the Commission, it contends that Hims\nengaged in:\n1. Deceptive Health Data Sharing: Despite extensive marketing campaigns\nemphasizing strict privacy, discreet telehealth consultations, and data\nprotection, the complaint alleges that Hims surreptitiously shared sensitive\nuser medical conditions and personal health data with third-party advertising\ngiants, including Meta Platforms (Facebook) and Snap, via embedded tracking\npixels and customer list matching.\n2. Subscription Billing & Cancellation Barriers (ROSCA Violations): The\nlawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act\n(ROSCA) by enrolling consumers in recurring subscription models without\ninformed consent. According to regulators, consumers were billed for\nprescriptions almost immediately upon completing an intake form—long before\nreceiving any consultation with a medical provider—while facing dark\npatterns and hidden cancellation options designed to prevent subscription\ntermination.\nThe market swiftly reacted, sending the price of Hims shares down $4.32\n(-14.7%) and erasing over $970 million from the company's market\ncapitalization in a single day.\n\n\"We're focused on whether Hims may have intentionally misled investors about\nits business practices, including the adequacy of its internal controls, and\nfinancial ramifications of the alleged misconduct,\" said Reed Kathrein\n(https://api.newsfilecorp.com/redirect/Q2WvNUpKjq), the Hagens Berman partner\nleading the firm's investigation.\n\nIf you invested in HIMS and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now\n(https://api.newsfilecorp.com/redirect/mjMNntk0vn) »\n\nWhistleblowers: Persons with non-public information regarding HIMS should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email HIMS@hbsslaw.com.\n\n# # #\n\nAbout Hagens Berman (https://api.newsfilecorp.com/redirect/kXMLWtQq4x)\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found at\nhbsslaw.com (https://api.newsfilecorp.com/redirect/B5QeYC2z1E). Follow the\nfirm for updates and news at @ClassActionLaw.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley,\nCA 94710, 844-916-0895, HIMS@hbsslaw.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316398","article_body_html":"","raw_payload":{"data":{"id":"nNFCbJzVY4-20260928","title":"Hims & Hers Health (HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS","author":"Newsfile Corp","ticker":"HIMS","created":"2026-09-28T20:25:18.436Z","tickers":["HIMS"],"exchange":"NYSE","article_body":"San Francisco, California--(Newsfile Corp. - September 28, 2026) - Hims & Hers\nHealth, Inc. (NYSE: HIMS) and certain company executives now face a securities\nclass action lawsuit stemming from the FTC's sweeping federal complaint\nagainst the company in which the Commission accuses Hims of serious business\nmisconduct.\n\nHagens Berman, which is actively investigating the alleged claims, encourages\nHIMS investors who suffered substantial losses to submit your losses now\n(https://api.newsfilecorp.com/redirect/Jk3XxIYqQn).\n\nClass Period: Aug. 4, 2025 – July 29, 2026\nLead Plaintiff Deadline: Nov. 2, 2026\nVisit Hims Investigation Page: www.hbsslaw.com/hims\nDirect Contact Email: HIMS@hbsslaw.com\nFirm Telephone: 844-916-0895\n\nHims & Hers Health ($HIMS) Securities Class Action\n\nThe lawsuit is focused on the propriety of Hims' repeated assurances that\n\"[w]e have developed and maintain policies and procedures with respect to\nhealth information and personal information that we use or disclose in\nconnection with our operations, including the adoption of administrative,\nphysical, and technical safeguards to protect such information.\"\n\nThe complaint alleges that Hims: (1) shared consumers' health information with\nthird-party advertising platforms; (2) charges consumers for prescriptions\nalmost immediately after they submit intake forms, despite telling them that\nthey will be able to consult with a medical provider to find a treatment that\nis \"right for them[;]\" and (3) as a result, would be subject to heightened\nregulatory scrutiny and likely to incur fees and penalties.\n\nWhat Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit\nBreakdown\n\nThe securities class action cites the July 29, 2026 federal complaint filed\nagainst Hims by the FTC—alongside co-plaintiffs the State of Utah and the\nCounty of Los Angeles (representing California).\n\nAfter an extensive investigation by the Commission, it contends that Hims\nengaged in:\n1. Deceptive Health Data Sharing: Despite extensive marketing campaigns\nemphasizing strict privacy, discreet telehealth consultations, and data\nprotection, the complaint alleges that Hims surreptitiously shared sensitive\nuser medical conditions and personal health data with third-party advertising\ngiants, including Meta Platforms (Facebook) and Snap, via embedded tracking\npixels and customer list matching.\n2. Subscription Billing & Cancellation Barriers (ROSCA Violations): The\nlawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act\n(ROSCA) by enrolling consumers in recurring subscription models without\ninformed consent. According to regulators, consumers were billed for\nprescriptions almost immediately upon completing an intake form—long before\nreceiving any consultation with a medical provider—while facing dark\npatterns and hidden cancellation options designed to prevent subscription\ntermination.\nThe market swiftly reacted, sending the price of Hims shares down $4.32\n(-14.7%) and erasing over $970 million from the company's market\ncapitalization in a single day.\n\n\"We're focused on whether Hims may have intentionally misled investors about\nits business practices, including the adequacy of its internal controls, and\nfinancial ramifications of the alleged misconduct,\" said Reed Kathrein\n(https://api.newsfilecorp.com/redirect/Q2WvNUpKjq), the Hagens Berman partner\nleading the firm's investigation.\n\nIf you invested in HIMS and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now\n(https://api.newsfilecorp.com/redirect/mjMNntk0vn) »\n\nWhistleblowers: Persons with non-public information regarding HIMS should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email HIMS@hbsslaw.com.\n\n# # #\n\nAbout Hagens Berman (https://api.newsfilecorp.com/redirect/kXMLWtQq4x)\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found at\nhbsslaw.com (https://api.newsfilecorp.com/redirect/B5QeYC2z1E). Follow the\nfirm for updates and news at @ClassActionLaw.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley,\nCA 94710, 844-916-0895, HIMS@hbsslaw.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316398"},"type":"article","timestamp":"2026-09-28T20:25:18.499844322Z","server_sent_at_ms":1790627118499},"received_at":"2026-09-28T20:25:18.571Z","source_url":"https://www.newsfilecorp.com/release/316398"},"analysis":{"id":"143340","press_release_id":"154580","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["FTC federal complaint with state co-plaintiffs alleging deceptive health-data sharing and ROSCA violations","Shares fell 14.7% in one day, erasing ~$970M in market cap","Potential penalties, fees, and heightened regulatory scrutiny","Whistleblower outreach to SEC program suggests ongoing investigation risk"],"eventType":"legal_litigation","narrative":"Hagens Berman announced a securities class action against Hims & Hers Health tied to the FTC's July 29, 2026 federal complaint, which was joined by Utah and Los Angeles County.\n\nThe release alleges Hims shared sensitive health data with ad platforms including Meta and Snap, and enrolled consumers in subscriptions without informed consent in violation of ROSCA.\n\nHIMS shares fell $4.32 (-14.7%) on the complaint's filing, erasing over $970 million in market cap; the lead plaintiff deadline is Nov. 2, 2026.\n\nThis notice is law-firm solicitation rather than issuer disclosure; the underlying FTC/regulatory risk remains the material story to track.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress, but flag the underlying FTC suit and regulatory overhang for monitoring."},"keyFigures":{"customDimensions":{"class_period":"Aug. 4, 2025 - July 29, 2026","stock_drop_pct":"-14.7%","market_cap_erased":"$970 million","stock_drop_dollars":"$4.32","lead_plaintiff_deadline":"Nov. 2, 2026"}},"quotedText":"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Hagens Berman partner leading investigation"}],"products":[],"companies":[{"name":"Hims & Hers Health, Inc.","ticker":"HIMS","relationship":"target of securities class action and FTC complaint"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Meta Platforms (Facebook)","relationship":"alleged recipient of shared health data"},{"name":"Snap","relationship":"alleged recipient of shared health data"}],"dollarAmounts":[{"amount":"$4.32","context":"single-day share price decline on July 29, 2026"},{"amount":"$970 million","context":"market capitalization erased in one day"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm (Hagens Berman) shareholder solicitation following the FTC lawsuit; no certified class or settlement announced. The release's purpose is soliciting plaintiffs, not issuer disclosure."},"tickerRelevance":{"others":[],"primary":"HIMS"},"globalImportance":20,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"high-profile retail-favorite mid-cap","eventGravity":"law-firm-solicitation-with-material-underlying-event","issuerAuthored":false,"retailFavoriteBoost":true}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman announced a securities class action against Hims & Hers Health tied to the FTC's July 29, 2026 federal complaint, which was joined by Utah and Los Angeles County.\n\nThe release alleges Hims shared sensitive health data with ad platforms including Meta and Snap, and enrolled consumers in subscriptions without informed consent in violation of ROSCA.\n\nHIMS shares fell $4.32 (-14.7%) on the complaint's filing, erasing over $970 million in market cap; the lead plaintiff deadline is Nov. 2, 2026.\n\nThis notice is law-firm solicitation rather than issuer disclosure; the underlying FTC/regulatory risk remains the material story to track.","key_figures":{"customDimensions":{"class_period":"Aug. 4, 2025 - July 29, 2026","stock_drop_pct":"-14.7%","market_cap_erased":"$970 million","stock_drop_dollars":"$4.32","lead_plaintiff_deadline":"Nov. 2, 2026"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Hagens Berman partner leading investigation"}],"products":[],"companies":[{"name":"Hims & Hers Health, Inc.","ticker":"HIMS","relationship":"target of securities class action and FTC complaint"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Meta Platforms (Facebook)","relationship":"alleged recipient of shared health data"},{"name":"Snap","relationship":"alleged recipient of shared health data"}],"dollarAmounts":[{"amount":"$4.32","context":"single-day share price decline on July 29, 2026"},{"amount":"$970 million","context":"market capitalization erased in one day"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T20:25:24.444Z","global_importance":20,"audience_relevance":45,"importance_components":{"tickerTier":"high-profile retail-favorite mid-cap","eventGravity":"law-firm-solicitation-with-material-underlying-event","issuerAuthored":false,"retailFavoriteBoost":true}},"durationMs":5857,"modelName":"glm-5.3-flashx"}}